RxDoctor Payments Data

Jeremy Avila, MD

Internal Medicine · Memphis, TNNPI 1497198865

Payments from drug & device makers

$14,027in general payments, 2019–2025

Across 876 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$756
  • Lilly USA, LLC$721
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$14,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk115$2,155
Amgen(2 entities)98$1,456
AbbVie(2 entities)112$1,315
AstraZeneca72$1,196
Pfizer61$756
Lilly USA, LLC46$721
GSK48$668
Takeda Pharmaceuticals U.S.A., Inc.23$507
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$432
Merck27$373
Daiichi Sankyo Inc.14$317
Teva Pharmaceuticals USA, Inc.16$312
Biohaven Pharmaceutical Holding Company Ltd.19$302
Boehringer Ingelheim14$266
Amarin Pharma, Inc.12$234
Abbott12$231
Eisai Inc.10$200
Biohaven Pharmaceuticals, Inc.14$200
Idorsia Pharmaceuticals US Inc16$192
Kowa Pharmaceuticals America, Inc.6$130
Corcept Therapeutics5$116
Tris Pharma Inc7$113
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$107
Esperion Therapeutics, Inc.6$107
Sanofi-aventis U.S. LLC5$100
Antares Pharma, Inc.4$93
Bayer6$90
Johnson & Johnson6$90
Amneal Pharmaceuticals LLC5$84
Radius Health, Inc.4$81
Lundbeck LLC3$70
Sumitomo Pharma America, Inc.3$57
Electromed, Inc.1$52
Ironwood Pharmaceuticals, Inc2$46
Phathom Pharmaceuticals, Inc.3$45
Corium, LLC3$44
Bristol Myers Squibb3$41
Otsuka America Pharmaceutical, Inc.2$41
Avanir Pharmaceuticals, Inc.2$41
Bausch Health US, LLC2$40
Genentech USA, Inc.2$39
Nevro Corp.2$38
Ultragenyx Pharmaceutical Inc.2$37
Abiomed1$35
Impel Pharmaceuticals Inc.2$35
Collegium Pharmaceutical, Inc.2$35
Dexcom, Inc.2$33
Medicure Pharma Inc.2$32
Sanofi1$32
Pacira Therapeutics, Inc.1$32
Exact Sciences2$30
Novartis2$29
UCB, Inc.2$28
Axsome Therapeutics, Inc.1$21
Xeris Pharmaceuticals, Inc.1$21
Inogen, Inc.1$19
Boston Scientific1$19
Apria Healthcare LLC1$18
Gilead1$17
Supernus Pharmaceuticals, Inc.1$15

How this compares

$14,027 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$271,070
Medicare patients
684
Services billed
13,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide101$126,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$91,969
FarxigaDapagliflozin Propanediol74$78,429
OzempicSemaglutide51$72,988
EliquisApixaban73$71,537
JardianceEmpagliflozin57$63,665
MyrbetriqMirabegron28$32,996
KerendiaFinerenone36$32,597
Synjardy XrEmpagliflozin/Metformin Hcl29$32,097
LinzessLinaclotide29$26,570
Trijardy XrEmpaglifloz/Linaglip/Metformin19$23,355
TrulicityDulaglutide19$21,453
Repatha SureclickEvolocumab19$18,093
Xigduo XrDapaglifloz Propaned/Metformin11$17,353
QuliptaAtogepant12$12,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$721$147,632120 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Combivent Respimat$266$125,374118 claims
GSKTrelegy Ellipta, Anoro Ellipta$668$97,105115 claims
AstraZenecaFarxiga$1,196$78,42974 claims
Novo NordiskOzempic$2,155$72,98851 claims
PfizerEliquis$756$71,53773 claims
AbbVieLinzess, Qulipta, Ubrelvy, Synthroid$1,315$56,973128 claims
BayerKerendia$90$32,59736 claims
Sumitomo Pharma America, Inc.Gemtesa$57$10,73614 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$84$3,851329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →